Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back

CCS/ACC JOINT PLENARY: ATRIAL FIBRILLATION MANAGEMENT

254 - COMPARISON OF ABLATION APPROACH TO MANAGEMENT

Friday, October 25, 2024
3:15 PM – 3:40 PM PT
Room: 211
On-Demand
Disclosure(s):
Jim Cheung: Biotronik: Consultant/Advisory Board (Ongoing); Boston Scientific: Speaker/Honoraria (Terminated, September 1, 2024); Medtronic: Speaker/Honoraria (Ongoing)
Carlos A. Morillo: Novartis: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
Justin Ezekowitz, MBBCh MSc: American Regent: Clinical Trials Site and/or Leadership (Ongoing); Applied Therapeutics: Clinical Trials Site and/or Leadership (Ongoing); Bayer: Clinical Trials Site and/or Leadership (Ongoing); Boerhinger-Ingelheim: Clinical Trials Site and/or Leadership (Ongoing); Cardurion: Clinical Trials Site and/or Leadership (Ongoing); CSL Vifor: Clinical Trials Site and/or Leadership (Ongoing); Merck: Clinical Trials Site and/or Leadership (Ongoing); Novartis: Clinical Trials Site and/or Leadership (Ongoing); Novo Nordisk: Clinical Trials Site and/or Leadership (Ongoing); Otsuka: Clinical Trials Site and/or Leadership (Ongoing)